Avita Medical Showcases 19 Clinical Presentations at Major Burn Conference
Avita Medical showcases wound care innovations at ABA 2026
Avita Medical (ASX: AVH) has announced its participation in the 2026 American Burn Association Annual Meeting, where the acute wound care company will present new clinical data across its product portfolio. The Avita Medical ABA 2026 presentation programme includes 19 investigator-led presentations alongside 3 company-sponsored events, demonstrating substantial clinical validation across RECELL, Cohealyx, and PermeaDerm technologies.
The conference, announced on 7 April 2026 from the company’s Valencia, California headquarters, will feature interim analysis from Avita Medical’s ongoing Cohealyx-I multi-centre study. This real-world data evaluation positions the company’s comprehensive wound management approach as addressing both clinical outcomes and hospital resource utilisation.
Cary Vance, Interim Chief Executive Officer
“The data being presented at ABA reinforces the strong clinical foundation behind RECELL, while introducing new case-based insights on Cohealyx and early findings from our ongoing multi-center real world study. Together, this work reflects a more complete approach to wound healing, one that not only closes wounds, but helps patients return to their lives faster.”
The extensive clinical programme signals continued validation of Avita Medical’s acute wound care platform in the burn treatment community.
When big ASX news breaks, our subscribers know first
What is Cohealyx and why does new data matter?
Cohealyx is a collagen-based dermal matrix designed to support readiness for skin grafting. The product supports tissue readiness before autograft procedures, with the Cohealyx-I multi-centre study evaluating time to skin grafting as a key clinical endpoint.
An interim analysis refers to a planned evaluation of study data before the trial completes. This allows researchers to assess early trends whilst patient enrolment and follow-up continue. For Cohealyx, the interim findings will be presented at Avita Medical’s symposium during the conference, offering early evidence of the product’s clinical utility in real-world settings.
The clinical pathway for Cohealyx follows a structured approach:
- Dermal matrix applied to the wound bed
- Matrix supports tissue preparation and readiness
- Wound becomes suitable for skin grafting procedures
- Study measures efficiency in time to grafting
This interim data matters because it provides early clinical validation for a relatively newer addition to Avita Medical’s portfolio. The findings could strengthen the commercial case for adoption in burn centres evaluating dermal matrix options.
RECELL evidence reinforces standard of care positioning
RECELL features prominently across the conference programme, with presentations spanning multiple clinical applications. A key finding from the Burn Center Quality Performance (BCQP) Registry analysis shows RECELL reduced hospital length of stay by 36% in patients with deep partial-thickness burns. This outcome directly addresses healthcare economic concerns facing hospital systems.
The conference presentations cover diverse RECELL applications, including facial burns, necrotising soft tissue infections, paediatric burns, and trauma wounds. RECELL GO, the automated cell preparation system, will be evaluated in a comparative presentation examining manual versus automated processing methods.
One presentation specifically addresses the new Current Procedural Terminology (CPT) codes for skin cell suspension autograft, examining how these codes impact payments, charges, and work credit for hospitals. This economic dimension matters for market adoption, as reimbursement clarity influences purchasing decisions.
| Product | Key Finding/Focus | Clinical Setting |
|---|---|---|
| RECELL | 36% length of stay reduction | Deep partial-thickness burns |
| RECELL GO | Manual vs automated comparison | Burn patient treatment |
| RECELL Mini | Paediatric application | Tertiary case study |
The breadth of presentations demonstrates ongoing clinical engagement with RECELL technology across diverse burn centre applications. The 36% reduction in hospital stay represents a quantifiable benefit that aligns with healthcare system priorities around cost management and bed capacity.
PermeaDerm adds complementary wound coverage
PermeaDerm, a biosynthetic wound matrix, completes Avita Medical’s acute wound care portfolio. The conference presentations will cover donor site management and full-thickness wound temporisation applications.
One presentation examines donor site healing time improvements when PermeaDerm is combined with RECELL autologous skin cell suspension. A retrospective review will assess PermeaDerm’s performance in split-thickness donor site management, providing real-world evidence of clinical utility.
The portfolio approach matters for commercial positioning. Burn centres managing complex cases require multiple treatment modalities, and a comprehensive product range creates cross-selling opportunities. Avita Medical positions itself as offering integrated solutions rather than single-point products.
The next major ASX story will hit our subscribers first
Strategic positioning through clinical conference presence
Avita Medical will debut a new booth experience at the conference centred on the theme “Healing at the Speed of Life”. This messaging represents a strategic shift from wound closure metrics toward recovery outcomes focused on mobility, function, and quality of life.
The repositioning reflects broader healthcare trends prioritising patient-reported outcomes alongside clinical endpoints. Hospital systems increasingly evaluate treatments based on how quickly patients return to normal activities, not merely how fast wounds close.
RECELL holds regulatory approvals across major markets:
- FDA approved in the US for thermal burn and trauma wounds
- CE mark in Europe for RECELL and RECELL GO
- TGA registered in Australia
- PMDA approval in Japan
This global regulatory footprint supports international commercialisation, though the US market remains the primary revenue driver. The conference presence reinforces clinical validation in the US burn care community, where key opinion leaders influence treatment protocol adoption.
The comprehensive presentation programme, spanning 19 investigator-led abstracts and 3 company-sponsored events, demonstrates sustained clinical interest in Avita Medical’s platform. For investors, this conference engagement signals ongoing evidence generation supporting the commercial thesis around acute wound care solutions that address both clinical outcomes and healthcare system efficiency.
Don’t Miss the Next Healthcare Innovation
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with expert analysis. The Big News Blast delivers market-moving healthcare announcements straight to your inbox before the broader market reacts. Click the “Free Alerts” button to get ahead on emerging medical technology breakthroughs.